Services on Demand
Anais Brasileiros de Dermatologia
Print version ISSN 0365-0596On-line version ISSN 1806-4841
LOYOLA, Adriano Jaime Consorte; CASTRO, Lia Cândida Miranda de; CHAIBUB, Sulamita Costa Wirth and XIMENES, Antônio Carlos. Infliximab in treatment of severe psoriatic arthritis. An. Bras. Dermatol. [online]. 2005, vol.80, n.5, pp.535-537. ISSN 0365-0596. http://dx.doi.org/10.1590/S0365-05962005000600012.
Psoriatic arthritis has been recognized as an auto-immune disease in which there is participation of the cytokine-producing T cells (tumor necrosis factor-alpha). Infliximab is a monoclonal antibody that binds to and inactivates tumor necrosis factor-alpha. Reported is a case of severe psoriatic arthritis which was unresponsive to multiple systemic therapies and treated with an intravenous infusion of infliximab, 5mg/Kg in three hours, in weeks 0,2,6 and 14, associated with a low dose of methotrexate, with an excellent therapeutical response.
Keywords : Arthritis, psoriatic; Tumor necrosis factor; Psoriasis.